301. High expression of PDGFA predicts poor prognosis of esophageal squamous cell carcinoma.
- Author
-
Han N, Zhang YY, Zhang ZM, Zhang F, Zeng TY, Zhang YB, and Zhao WC
- Subjects
- Biomarkers, Tumor analysis, Biomarkers, Tumor metabolism, Carcinogenesis genetics, Datasets as Topic, Esophageal Mucosa pathology, Esophageal Mucosa surgery, Esophageal Neoplasms diagnosis, Esophageal Neoplasms mortality, Esophageal Neoplasms surgery, Esophageal Squamous Cell Carcinoma diagnosis, Esophageal Squamous Cell Carcinoma mortality, Esophageal Squamous Cell Carcinoma surgery, Esophagectomy, Follow-Up Studies, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Staging, Oligonucleotide Array Sequence Analysis, Platelet-Derived Growth Factor, Prognosis, Up-Regulation, Biomarkers, Tumor genetics, Esophageal Neoplasms genetics, Esophageal Squamous Cell Carcinoma genetics
- Abstract
Abstract: Platelet-derived growth factor A (PDGFA), the most known member of PDGF family, plays a crucial role in occurrence and progression of different tumors. However, PDGFA expression and its clinical significance in esophageal squamous cell carcinoma (ESCC) are not clear. The present study aimed to assess the expression and prognostic value of PDGFA in ESCC.The Gene Expression Omnibus databases (GSE53625, GSE23400, and GSE67269) and fresh clinical samples were employed for detecting PDGFA messenger RNA expression in ESCC. The associations of PDGFA expression with clinicopathological characteristics were evaluated by chi-square test. Kaplan-Meier analysis and Cox proportional hazard regression model were performed to determine the prognostic value of PDGFA in ESCC patients. PDGFA-related signaling pathways were defined by gene set enrichment analysis based on Gene Expression Omnibus databases.The PDGFA messenger RNA expression was upregulated in ESCC tissues compared with paired adjacent noncancerous tissues (P < .05) and was positively correlated with T stage (P < .05). Kaplan-Meier survival analysis suggested that ESCC patients with high PDGFA expression were associated with poorer overall survival compared to those with low PDGFA expression (P < .05), especially in advanced T stage (P < .05). Cox analyses showed that high expression of PDGFA was an independent predictor for poor prognosis in ESCC patients. Gene set enrichment analysis identified 3 signaling pathways (extracellular matrix receptor interaction, focal adhesion, and glycosaminoglycan biosynthesis chondroitin sulfate) that were enriched in PDGFA high expression phenotype (all P < .01).PDGFA may serve as an oncogene in ESCC and represent an independent molecular biomarker for prognosis of ESCC patients., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2021
- Full Text
- View/download PDF